anti sirt 3 antibody (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
86
Structured Review
Cell Signaling Technology Inc
anti sirt 3 antibody
Anti Sirt 3 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirt/pm41683751-175-18-20
Average 86 stars, based on 1 article reviews
Anti Sirt 3 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirt/pm41683751-175-18-20
Average 86 stars, based on 1 article reviews
anti sirt 3 antibody - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
other:Article Title: Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications Article Snippet: Article Title: High-Intensity Interval Training Remodels the Proteome and Acetylome of Human Skeletal Muscle Article Snippet: MFN2: #11925, Cell Signaling 772 Technologies, 80 kDa; MYLK2: PA5-29324, Invitrogen, 65 kDa; NAMPT: A300-779A, Bethyl 773 Laboratories, 56 kDa; OXPHOS antibody cocktail: ab110411, Abcam, 15-55 kDa; SIRT-1: 07-131, 774 Millipore, 80 kDa; Western Blot:Article Title: Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice. Article Snippet: The lysates were then used in BCA protein assay kit (Thermo Fisher, No. 23225) to measure total protein. .. The total protein amounts of 8–12lg per sample were used for running into the premade (Bio-Rad) gel running at 100 V for 1 h. Proteins were then transferred to nitrocellulose membranes with Bio-Rad transfer system (Trans-Blot Turbo) and blocked in 1 Quant Clean Western buffer (cat No. R2001) for 1 h. The blots were then incubated with dilute primary antibody in 5% BSA, 1 TBS, 0.1% Tween-20 at 4 C with gentle shaking, overnight ( Incubation:Article Title: Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice. Article Snippet: The lysates were then used in BCA protein assay kit (Thermo Fisher, No. 23225) to measure total protein. .. The total protein amounts of 8–12lg per sample were used for running into the premade (Bio-Rad) gel running at 100 V for 1 h. Proteins were then transferred to nitrocellulose membranes with Bio-Rad transfer system (Trans-Blot Turbo) and blocked in 1 Quant Clean Western buffer (cat No. R2001) for 1 h. The blots were then incubated with dilute primary antibody in 5% BSA, 1 TBS, 0.1% Tween-20 at 4 C with gentle shaking, overnight ( Gentle:Article Title: Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice. Article Snippet: The lysates were then used in BCA protein assay kit (Thermo Fisher, No. 23225) to measure total protein. .. The total protein amounts of 8–12lg per sample were used for running into the premade (Bio-Rad) gel running at 100 V for 1 h. Proteins were then transferred to nitrocellulose membranes with Bio-Rad transfer system (Trans-Blot Turbo) and blocked in 1 Quant Clean Western buffer (cat No. R2001) for 1 h. The blots were then incubated with dilute primary antibody in 5% BSA, 1 TBS, 0.1% Tween-20 at 4 C with gentle shaking, overnight ( |
![The regulation of H3K18ac by BRD3 degradation is mediated by HDACs, and CCL5 is its target (A) The expression of several deacetylase enzymes (HDAC1, HDAC2, Sirt1, and Sirt3) in control group, LPS group, and D072 treatment group experiments in vitro . (B) The expression levels of SIRT1 under various treatments (LPS stimulation, D072 treatment, or siBRD3 knockdown), Sirt1 changes in proteins and mRNA. (C) The mRNA levels of cxcl10, ccl5, HK3, and nos2 in control group, LPS group, D072 treatment group, D072 + SIRT1 inhibitor (EX-527 treated) group in vitro . (D) The expression levels of CCL5, CXCL10, HK3, and NO2 under the intervention of each group of HDAC inhibitors. (Inhibitor terminology and function: SB: sodium butanoate [HDACs inhibitor], EX-527 <t>[SIRT1</t> <t>inhibitor],</t> <t>SIRT-IN-2</t> [SIRT1, 2, 3 inhibitors], SIRT6-IN-5 [SIRT6 inhibitor], and 97491 [SIRT7 inhibitor]). (E) The expression changes of H3K18ac under the intervention of each group of HDAC inhibitors. (Inhibitor terminology and function: SB: sodium butanoate [HDACs inhibitor], EX-527 [SIRT1 inhibitor], SIRT-IN-2 [SIRT1, 2, 3 inhibitors], SIRT6-IN-5 [SIRT6 inhibitor], and 97491 [SIRT7 inhibitor]). (A) Upper: representative western blot images of HDAC1, HDAC2, SIRT1, and SIRT3 in each group. Lower: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ns, p > 0.05, ∗p < 0.05, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images and the corresponding quantification of the relative protein levels of SIRT1 in each group. Right: quantification of the relative mRNA changes of the SIRT1 in different groups. ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (C) Quantification of the mRNA level of Cxcl10 , Ccl5 , Hk3 , and inos after SIRT1 inhibitor EX-527 treatment. ( n = 3/group; mean ± SD; ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (D) Quantification of the mRNA level of Cxcl10 , Ccl5 , Hk3 , and inos under different HDAC inhibitor treatment. ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). Inhibitor terminology and function: SB: sodium butanoate (HDACs inhibitor), EX-527 (SIRT1 inhibitor), SIRT-IN-2 (SIRT1, 2, 3 inhibitors), SIRT6-IN-5 (SIRT6 inhibitor), and 97491 (SIRT7 inhibitor). (E) Quantification of the relative H3K18ac protein level under each treatment. ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (F) Left: transwell images of different groups; scale bars: 100 μm. Right: quantification of migration cells under each treatment. ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (G) Quantification statistics concentration of CCL5 in each group. ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA).](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_8559/pmc12828559/pmc12828559__gr6.jpg)